Acrux

Acrux SGA/Revenue

The SGA to Revenue Ratio of Acrux (ACR.AX) as of Oct 20, 2026 is 104.52 %. In the previous year, SGA to Revenue Ratio was 484.62 % — a change of -78.43% (lower).

SGA/Revenue

104.52 %

YoY

-78.43%

Last updated:

SGA to Revenue Ratio of Acrux is 2026 104.52 % . SGA to Revenue Ratio of Acrux was 2025 484.62 % . It decreases by -78.43% lower compared to the previous year.

The Acrux SGA/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

SGA/Revenue
Date
SGA/Revenue
Jan 1, 2019
173.53 AUD
Jan 1, 2020
55.55 AUD
Jan 1, 2021
61.93 AUD
Jan 1, 2022
37.17 AUD
Jan 1, 2023
6.31 AUD
Jan 1, 2024
113.42 AUD
Jan 1, 2025
484.62 AUD
Jan 1, 2026
104.52 AUD
The Acrux SGA/Revenue history
YEARSGA/RevenueYoY
104.52 %-78.43%
484.62 %+327.30%
113.42 %+1,696.96%
6.31 %-83.02%
37.17 %-39.98%
61.93 %+11.49%
55.55 %-67.99%
173.53 %+96.49%
88.32 %+856.88%
9.23 %+187.74%
3.21 %-29.06%
4.52 %+170.58%
1.67 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrux Stock analysis

What does Acrux do? Acrux Ltd is an Australian pharmaceutical company specializing in the development and marketing of products in the dermatology field. The company was founded in 1998 and is headquartered in Melbourne. Its history begins with the development of a groundbreaking technology called the "Sprayform® Technology," which allows the administration of liquid medications in spray form, providing numerous advantages compared to traditional administration methods. Acrux obtained the first patent for this technology in 1999 and worked on bringing it to the market. Its business model focuses on licensing its Sprayform® Technology to third parties to advance the development and marketing of products in various therapeutic areas. The company has an experienced research and development team that collaborates closely with partners to develop tailored solutions and support the entire development process, ensuring that all products meet the highest quality standards and regulatory requirements. Acrux Ltd is divided into various divisions, including products for women, diabetes, pain and inflammation, as well as neurology and psychiatry. With its Sprayform® Technology, the company has developed unique therapeutic solutions that meet patients' needs. For example, a testosterone preparation for women has been developed that is simply applied as a spray and offers higher efficacy than traditional tablets. Another product is a fast-acting pain reliever that is administered through a nasal spray. Acrux Ltd also has partnerships with major pharmaceutical companies such as Eli Lilly, Johnson & Johnson, Pfizer, and Sanofi. These partnerships enable Acrux to market its technology globally and offer its customers a comprehensive portfolio of tailored solutions. The partner is granted exclusive rights to use the technology for specific products and markets, facilitating the development of new products and the expansion into new regions. Overall, Acrux Ltd has achieved a leadership position in the field of transdermal systems and transmucosal technologies through its innovative Sprayform® Technology. The company aims to further expand its leadership position by focusing on the development of new products and collaboration with partners. Acrux remains in constant exchange with the scientific community to incorporate the latest research and development insights into its products. Acrux is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrux stock

SGA to Revenue Ratio of Acrux is 104.52 % in 2026.

SGA to Revenue Ratio of Acrux changed from 484.62 % to 104.52 %, representing a -78.43% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of SGA to Revenue Ratio Acrux since 2006 – with annual values, charts, and detailed analysis.

The SGA/Revenue ratio shows what percentage of revenue is consumed by selling, general, and administrative costs. Lower ratios indicate greater operating efficiency.

A 'good' varies by industry and company stage. On Eulerpool, you can compare SGA to Revenue Ratio's Acrux with sector peers and the industry average to assess whether it is attractive.

To evaluate SGA to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for SGA to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Acrux

All Key Metrics — Acrux